Please use this identifier to cite or link to this item:
Title: Antibiotic Management of Lung Infections in Cystic Fibrosis. II. Nontuberculous Mycobacteria, Anaerobic Bacteria, and Fungi
Authors: Chmiel, James F.
Aksamit, Timothy R.
Chotirmall, Sanjay Haresh
Dasenbrook, Elliott C.
Stuart Elborn, J.
LiPuma, John J.
Ranganathan, Sarath C.
Waters, Valerie J.
Ratjen, Felix A.
Keywords: Anaerobic bacteria
Aspergillus fumigatus
Issue Date: 2014
Source: Chmiel, J. F., Aksamit, T. R., Chotirmall, S. H., Dasenbrook, E. C., Stuart Elborn, J., LiPuma, J. J., et al. (2014). Antibiotic Management of Lung Infections in Cystic Fibrosis. II. Nontuberculous Mycobacteria, Anaerobic Bacteria, and Fungi. Annals of the American Thoracic Society, 11(8), 1298-1306.
Series/Report no.: Annals of the American Thoracic Society
Abstract: Airway infections are a key component of cystic fibrosis (CF) lung disease. Whereas the approach to common pathogens such as Pseudomonas aeruginosa is guided by a significant body of evidence, other infections often pose a considerable challenge to treating physicians. In Part I of this series on the antibiotic management of difficult lung infections, we discussed bacterial organisms including methicillin-resistant Staphylococcus aureus, gram-negative bacterial infections, and treatment of multiple bacterial pathogens. Here, we summarize the approach to infections with nontuberculous mycobacteria, anaerobic bacteria, and fungi. Nontuberculous mycobacteria can significantly impact the course of lung disease in patients with CF, but differentiation between colonization and infection is difficult clinically as coinfection with other micro-organisms is common. Treatment consists of different classes of antibiotics, varies in intensity, and is best guided by a team of specialized clinicians and microbiologists. The ability of anaerobic bacteria to contribute to CF lung disease is less clear, even though clinical relevance has been reported in individual patients. Anaerobes detected in CF sputum are often resistant to multiple drugs, and treatment has not yet been shown to positively affect patient outcome. Fungi have gained significant interest as potential CF pathogens. Although the role of Candida is largely unclear, there is mounting evidence that Scedosporium species and Aspergillus fumigatus, beyond the classical presentation of allergic bronchopulmonary aspergillosis, can be relevant in patients with CF and treatment should be considered. At present, however there remains limited information on how best to select patients who could benefit from antifungal therapy.
Description: 36 p.
ISSN: 2329-6933
DOI: 10.1513/AnnalsATS.201405-203AS
Schools: Lee Kong Chian School of Medicine (LKCMedicine) 
Rights: © 2014 American Thoracic Society. This is the author created version of a work that has been peer reviewed and accepted for publication by Annals of the American Thoracic Society, American Thoracic Society. It incorporates referee’s comments but changes resulting from the publishing process, such as copyediting, structural formatting, may not be reflected in this document. The published version is available at: [].
Fulltext Permission: open
Fulltext Availability: With Fulltext
Appears in Collections:LKCMedicine Journal Articles

Citations 5

Updated on Jun 10, 2024

Page view(s) 50

Updated on Jun 12, 2024

Download(s) 50

Updated on Jun 12, 2024

Google ScholarTM




Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.